Medicenna Therapeutics Stock (OTC: MDNAF)

Medicenna Therapeutics (OTC:MDNAF) Stock, Quote.Headers.trade-ideas

Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL13 Superkines and Empowered Superkines for the treatment of cancer and other diseases. Its pipeline candidates include MDNA55 for recurrent glioblastoma multiforme (rGBM), MDNA11 for Cancer immunotherapies, MDNA209 for Autoimmune Diseases, MDNA413 for Cancer immunotherapies, and MDNA132 for Solid Tumors, BiSKITs represents the novel platform comprised of Bifunctional SuperKine ImmunoTherapies.

Penny Stocks

MDNAF

TSX:MDNA


  By David Bautz, PhD

TSX:MDNA.TO | OTC:MDNAF

READ THE FULL MDNA.TO RESEARCH REPORT

MDNA.TO: Data on MDNA55 and MDNA11 to be Presented at ASCO 2020…

Biotech

Long Ideas

News

Short Ideas

Emerging Markets

Specialty ETFs

Eurozone

Health Care

Global

Markets

Trading Ideas

ETFs

General

ADRNY

AXAHY

CYDY

DANOY

EXPGY

FNMA

GAXY

GBTC

HEINY

IMBBY

IPIX

JBSAY

KBLB

RHHBY

TOMDF

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

The COVID-19 pandemic has led to dramatic changes in market behavior, as traders and investors try to grapple with the short-term and long-term implications of a pandemic.

The Spread of COVID-19 Has Caused Massive Volume Spikes In Securities On OTC Markets

MDNA.TO: Encouraging MDNA19 Data in Non-Human Primates; Financing Funds Company Through End of 2022…

MEDICENNA THERA CORP by Medicenna Therapeutics Corp.

Medicenna Therapeutics Corp

<p>Craig-Hallum  analyst Christian Schwab   maintains A10 Networks (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATEN#NYSE">ATEN</a>) with a Hold and raises the price target from $16 to $18.</p>


Price Target

Analyst Ratings

ATEN

Craig-Hallum Maintains Hold on A10 Networks, Raises Price Target to $18

<p><strong>Berkshire Hathaway Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>)(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) CEO <strong>Warren Buffett </strong>was able to once again beat the performance of the <strong>S&amp;P 500</strong> in 2024, which came as he sold shares of several of his larger positions and added to<a href="https://www.benzinga.com/general/education/25/01/42832123/warren-buffett-beats-sp-500-in-2024-how-oracle-of-omahas-returns-compare-over-past-20-years"> his cash balance.</a></p>
<p>Buffett isn't buying much, but one stock continues to catch his attention.</p>
<p><strong>What Happened: </strong>Buffett has invested <a href="https://www.benzinga.com/general/education/24/08/40652464/warren-buffett-celebrates-94th-birthday-with-1-trillion-market-cap-milestone-a-look-back-at-hig">in value stocks </a>over the years, preferring this method of investing in companies trading below their value over investing in unprofitable growth stocks.</p>
<p>This might explain why Buffett could be the reason Berkshire Hathaway is scooping up more shares of satellite radio company <strong>Sirius XM Holdings Inc </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIRI#NASDAQ">SIRI</a>).</p>
<p>A new SEC <a href="https://investor.siriusxm.com/sec-filings/all-sec-filings##document-6883-0000950170-25-012600-2">filing </a>showed Berkshire Hathaway purchased 2,308,119 shares for around $54 million from Jan. 30 through Feb. 3.</p>
<p>The purchases came after Sirius XM Holdings reported fourth-quarter financial results that <a href="https://www.benzinga.com/news/earnings/25/01/43345721/sirius-xm-q4-earnings-beats-estimates-ceo-highlights-focus-on-in-car-subscriptions-ad-supported-growth">beat analyst estimates.</a></p>
<p>Berkshire Hathaway now owns 119,776,692 Sirius XM shares — around 35.4% of the company, as reported by <a href="https://www.cnbc.com/amp/2025/02/04/warren-buffetts-berkshire-hathaway-scoops-up-more-sirius-xm-boosting-stake-to-35percent.html">CNBC</a>.</p>
<p>The firm first bought <strong>Liberty Media</strong> stocks in 2016. It later added to its Sirius XM-specific stake in 2024 as Liberty underwent changes to its public holding companies.</p>
<p><strong>You may not be a billionaire like Warren Buffett, but you can uncover hidden gems in the stock market using our proprietary data and pattern recognition — </strong><a href="https://www.benzinga.com/trading-ideas/25/02/43419547/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-52"><strong>check out five stocks flying under the radar that deserve your attention.</strong></a></p>
<p><strong>Why It's Important:</strong> Buffett has not publicly commented on Sirius XM Holdings. It&#8217;s also unclear whether it&#8217;s him or another Berkshire investor buying the shares.</p>
<p>Berkshire Hathaway also added Sirius XM shares in December. The move came as the Buffett-led conglomerate held its cash and sat on the sidelines of the stock market.</p>
<p>Sirius XM stock is down 52% over the last year. This could make the stock a value play with the right financials.</p>
<p>During the fourth-quarter results, Sirius XM CEO<strong> Jennifer Witz</strong> put an emphasis on the company prioritizing its in-car subscription business, leveraging streaming capabilities and growing its ad-supported audio.</p>
<p>The company currently trades with a price-to-earnings ratio of 7.03x and has a price-to-sales ratio of 0.96x, both considered cheap for value stocks.</p>
<p>Investors are eagerly awaiting public comments from Buffett on why Berkshire Hathaway is a big buy from the company. Until then, investors may just have to invest alongside the Oracle of Omaha or take a wait and see approach.</p>
<p><strong>Price Action:</strong> Sirius XM Holdings stock trades at $24.62 on Wednesday versus a 52-week trading range of $20.47 to $51.80.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/top-stories/24/12/42706002/warren-buffett-said-selling-disney-was-a-huge-mistake-legendary-investor-should-have-been-buying">Warren Buffett Said Selling Disney &#8216;Was A Huge Mistake&#8217;: Legendary Investor &#8216;Should Have Been Buying&#8217;</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Entertainment

SIRI

Warren Buffett Buys More Shares Of Stock Down 52% Over Last Year: Here's What The Oracle Of Omaha Purchased

<p>Deep-pocketed investors have adopted a bearish approach towards CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CRWD usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for CrowdStrike Holdings. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 20% leaning bullish and 60% bearish. Among these notable options, 2 are puts, totaling $151,190, and 8 are calls, amounting to $358,180.</p>
<h3>Expected Price Movements</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $250.0 and $430.0 for CrowdStrike Holdings, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for CrowdStrike Holdings's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of CrowdStrike Holdings's whale activity within a strike price range from $250.0 to $430.0 in the last 30 days. </p>
<h3>CrowdStrike Holdings Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1738770336_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CRWD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$28.55</td>
<td>$27.9</td>
<td>$28.3</td>
<td>$330.00</td>
<td>$121.6K</td>
<td>1.1K</td>
<td align="right">73</td>
</tr>
<tr>
<td>CRWD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$41.0</td>
<td>$37.4</td>
<td>$40.0</td>
<td>$400.00</td>
<td>$68.0K</td>
<td>560</td>
<td align="right">18</td>
</tr>
<tr>
<td>CRWD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>02/14/25</td>
<td>$14.5</td>
<td>$13.9</td>
<td>$13.95</td>
<td>$405.00</td>
<td>$65.7K</td>
<td>171</td>
<td align="right">0</td>
</tr>
<tr>
<td>CRWD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/14/25</td>
<td>$14.3</td>
<td>$13.75</td>
<td>$13.75</td>
<td>$405.00</td>
<td>$48.3K</td>
<td>171</td>
<td align="right">272</td>
</tr>
<tr>
<td>CRWD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$142.45</td>
<td>$140.05</td>
<td>$141.0</td>
<td>$300.00</td>
<td>$42.3K</td>
<td>1.1K</td>
<td align="right">21</td>
</tr>
</tbody>
</table>
</p>
<h3>About CrowdStrike Holdings</h3>
<p>CrowdStrike is a cloud-based cybersecurity company specializing in next-generation security verticals such as endpoint, cloud workload, identity, and security operations. CrowdStrike's primary offering is its Falcon platform that offers a proverbial single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The Texas-based firm was founded in 2011 and went public in 2019.</p>
<h3>Current Position of CrowdStrike Holdings</h3>
<ul>
<li>Trading volume stands at 593,855, with CRWD's price up by 0.05%, positioned at $407.74.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 27 days.</li>
</ul>
<h3>Professional Analyst Ratings for CrowdStrike Holdings</h3>
<p>Over the past month, 4 industry analysts have shared their insights on this stock, proposing an average target price of $401.25.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; In a cautious move, an analyst from Baird downgraded its rating to Neutral, setting a price target of $430.<br />
&#x2A; An analyst from Scotiabank has decided to maintain their Sector Perform rating on CrowdStrike Holdings, which currently sits at a price target of $370.<br />
&#x2A; An analyst from Citigroup has decided to maintain their Buy rating on CrowdStrike Holdings, which currently sits at a price target of $420.<br />
&#x2A; An analyst from Truist Securities has decided to maintain their Buy rating on CrowdStrike Holdings, which currently sits at a price target of $385. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for CrowdStrike Holdings with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Options

CRWD

A Closer Look at CrowdStrike Holdings's Options Market Dynamics

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>PayPal Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with PYPL, it often means somebody knows something is about to happen.</p>
<p>Today, Benzinga's options scanner spotted 11 options trades for <strong>PayPal Holdings</strong>.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 45% bullish and 45%, bearish.</p>
<p>Out of all of the options we uncovered, there was 1 put, for a total amount of $38,478, and 10, calls, for a total amount of $490,761.</p>
<h3>What's The Price Target?</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $60.0 to $95.0 for PayPal Holdings over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In today's trading context, the average open interest for options of PayPal Holdings stands at 4210.45, with a total volume reaching 8,919.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in PayPal Holdings, situated within the strike price corridor from $60.0 to $95.0, throughout the last 30 days.</p>
<h3>PayPal Holdings 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1738770330_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>PYPL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/14/25</td>
<td>$2.3</td>
<td>$2.02</td>
<td>$2.1</td>
<td>$78.00</td>
<td>$101.8K</td>
<td>2.5K</td>
<td>485</td>
</tr>
<tr>
<td>PYPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$1.47</td>
<td>$1.42</td>
<td>$1.46</td>
<td>$80.00</td>
<td>$72.6K</td>
<td>8.6K</td>
<td>5.6K</td>
</tr>
<tr>
<td>PYPL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/28/25</td>
<td>$2.3</td>
<td>$2.23</td>
<td>$2.3</td>
<td>$80.00</td>
<td>$57.5K</td>
<td>854</td>
<td>392</td>
</tr>
<tr>
<td>PYPL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$4.35</td>
<td>$3.9</td>
<td>$4.05</td>
<td>$80.00</td>
<td>$45.3K</td>
<td>1.8K</td>
<td>114</td>
</tr>
<tr>
<td>PYPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/07/25</td>
<td>$3.2</td>
<td>$3.1</td>
<td>$3.1</td>
<td>$76.00</td>
<td>$40.9K</td>
<td>254</td>
<td>158</td>
</tr>
</tbody>
</table>
</p>
<h3>About PayPal Holdings</h3>
<p>PayPal was spun off from eBay in 2015 and provides electronic payment solutions to merchants and consumers, with a focus on online transactions. The company had 426 million active accounts at the end of 2023. The company also owns Venmo, a person-to-person payment platform.</p>
<h3>PayPal Holdings's Current Market Status</h3>
<ul>
<li>Trading volume stands at 7,001,787, with PYPL's price up by 1.6%, positioned at $78.97.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 83 days.</li>
</ul>
<h3>Professional Analyst Ratings for PayPal Holdings</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $89.8.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Wells Fargo persists with their Equal-Weight rating on PayPal Holdings, maintaining a target price of $80.<br />
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Buy rating on PayPal Holdings with a target price of $97.<br />
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Equal-Weight rating for PayPal Holdings, targeting a price of $79.<br />
&#x2A; An analyst from Citigroup persists with their Buy rating on PayPal Holdings, maintaining a target price of $98.<br />
&#x2A; Consistent in their evaluation, an analyst from Baird keeps a Outperform rating on PayPal Holdings with a target price of $95. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for PayPal Holdings with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


PYPL

Behind the Scenes of PayPal Holdings's Latest Options Trends

<p>High-rolling investors have positioned themselves bullish on Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), and it's important for retail traders to take note.<br />
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in AMGN often signals that someone has privileged information.</p>
<p>Today, Benzinga's options scanner spotted 9 options trades for Amgen. This is not a typical pattern.</p>
<p>The sentiment among these major traders is split, with 66% bullish and 0% bearish. Among all the options we identified, there was one put, amounting to $25,560, and 8 calls, totaling $578,729.</p>
<h3>What's The Price Target?</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $250.0 to $320.0 for Amgen during the past quarter. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Amgen options trades today is 1031.71 with a total volume of 3,367.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Amgen's big money trades within a strike price range of $250.0 to $320.0 over the last 30 days.</p>
<h3>Amgen 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1738770325_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$21.0</td>
<td>$20.3</td>
<td>$20.81</td>
<td>$285.00</td>
<td>$252.8K</td>
<td>4.5K</td>
<td align="right">964</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$20.9</td>
<td>$20.25</td>
<td>$20.7</td>
<td>$285.00</td>
<td>$92.9K</td>
<td>4.5K</td>
<td align="right">365</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$10.7</td>
<td>$10.2</td>
<td>$10.25</td>
<td>$320.00</td>
<td>$58.4K</td>
<td>624</td>
<td align="right">462</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$10.9</td>
<td>$10.45</td>
<td>$10.7</td>
<td>$300.00</td>
<td>$53.5K</td>
<td>982</td>
<td align="right">249</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$21.25</td>
<td>$19.7</td>
<td>$20.8</td>
<td>$285.00</td>
<td>$35.3K</td>
<td>4.5K</td>
<td align="right">407</td>
</tr>
</tbody>
</table>
</p>
<h3>About Amgen</h3>
<p>Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.</p>
<p>In light of the recent options history for Amgen, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Current Position of Amgen</h3>
<ul>
<li>With a trading volume of 1,699,750, the price of AMGN is up by 5.44%, reaching $304.74.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 85 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Amgen</h3>
<p>In the last month, 4 experts released ratings on this stock with an average target price of $299.25.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Wells Fargo has decided to maintain their Equal-Weight rating on Amgen, which currently sits at a price target of $280.<br />
&#x2A; Maintaining their stance, an analyst from Truist Securities continues to hold a Hold rating for Amgen, targeting a price of $298.<br />
&#x2A; An analyst from Citigroup persists with their Neutral rating on Amgen, maintaining a target price of $295.<br />
&#x2A; An analyst from RBC Capital has revised its rating downward to Outperform, adjusting the price target to $324. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Amgen with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


AMGN

Amgen Options Trading: A Deep Dive into Market Sentiment

<p><strong>Marc Andreessen</strong>, a major tech investor and cofounder of venture capital firm Andreessen Horowitz, believes AI will drastically reshape the economy by crashing wages while also driving down the cost of goods and services.&nbsp;</p>
<h2 class="wp-block-heading">The Promise of a Consumer Utopia</h2>
<p>In a recent <a href="https://x.com/pmarca/status/1882993091784880557">tweet</a>, Andreessen claimed that the fall in human wages due to AI is not only logical but necessary. &#8220;A world in which human wages crash from AI – logically, necessarily – is a world in which productivity growth goes through the roof, and prices for goods and services crash to near zero,&#8221; he wrote. &#8220;Consumer cornucopia. Everything you need and want for pennies.&#8221;</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">A world in which human wages crash from AI &#8212; logically, necessarily &#8212; is a world in which productivity growth goes through the roof, and prices for goods and services crash to near zero. Consumer cornucopia. Everything you need and want for pennies.</p>
<p>&mdash; Marc Andreessen &#x1f1fa;&#x1f1f8; (@pmarca) <a href="https://twitter.com/pmarca/status/1882993091784880557?ref_src=twsrc%5Etfw">January 25, 2025</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p><strong>Don't Miss:</strong></p>
<ul>
<li><strong>Over the last five years, the price of gold has increased by approximately 83% — Investors like Bill O&#8217;Reilly and Rudy Giuliani are using this platform to <a href="https://www.benzinga.com/money/american-hartford-gold"><strong>create customized gold IRAs to help shield their savings from inflation and economic turbulence. </strong></a></strong></li>
<li><strong>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2"><strong>Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</strong></a></strong></li>
</ul>
<p>As Futurism reports, this follows a well-worn Silicon Valley belief that technological progress inevitably results in widespread prosperity. The idea is that, as AI boosts productivity to unprecedented levels, prices will plummet, making life more affordable even if people are earning far less. However, this assumes that people will still have enough income to participate in this supposed economic utopia.</p>
<h2 class="wp-block-heading">The Ruthless Logic of Silicon Valley</h2>
<p>Andreessen's vision highlights how many tech leaders see the future: temporary economic struggles are just part of progress. However, his comments also suggest that these investors care more about changing things quickly than about workers losing their jobs.</p>
<p>For instance, while some AI proponents <a href="https://www.benzinga.com/personal-finance/25/01/43255222/bill-gates-wants-to-tax-the-robots-that-take-your-job-and-some-say-it-could-fund-universal-basic-income-to-replace-lost-wages">advocate for universal basic income (UBI)</a> as a safety net for displaced workers, Andreessen is staunchly against it, comparing it in his infamous &#8220;The Techno-Optimist Manifesto&#8221; to turning people into &#8220;zoo animals.&#8221; Instead of offering solutions to mitigate AI's impact, he appears to view the collapse of traditional jobs as an unavoidable consequence of progress.</p>
<p><strong>Trending: Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-nancy-pelosi"><strong>Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000</strong></a></strong></p>
<h2 class="wp-block-heading">A Broader Pattern of Disdain for Workers</h2>
<p>Andreessen's rhetoric isn&#8217;t an isolated case. <strong>Elon Musk</strong> shares a similar philosophy and <a href="https://www.benzinga.com/personal-finance/24/11/41701075/elon-musk-warns-of-hardship-for-americans-if-trump-puts-him-in-charge-of-cutting-33-trillion-deb">commented in November</a> that his DOGE commission's work would "necessarily involve some temporary hardship." Oracle cofounder <strong>Larry Ellison</strong> supports AI being <a href="https://www.benzinga.com/news/24/09/40892284/oracles-larry-ellison-predicts-police-officers-will-be-supervised-at-all-times-and-citizens-will-be">used for government surveillance</a>, saying it will make sure &#8220;citizens will be on their best behavior.&#8221;</p>
<p>Andreessen has also expressed deep suspicion toward the workers inside his companies. In a recent interview with NYT&#8217;s Ross Douthat, he claimed that elite institutions are producing &#8220;America-hating communists&#8221; who infiltrate his firms and actively work to destroy them from the inside. He views these people as &#8220;professional activists&#8221; who undermine companies rather than help them, strengthening his argument for using AI to replace human labor.</p>
<p><strong><em>See Also: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"><strong><em> </em></strong><strong><em>you can become an investor for $0.80 per share today.</em></strong></a></em></strong></p>
<h2 class="wp-block-heading">The Future of AI and the Economy</h2>
<p>Andreessen and other Silicon Valley elites continue to push the narrative that AI's disruptive potential is an unavoidable step toward a better future. However, a big part of their worldview is predicated on the idea that people would adapt and that new opportunities will inevitably arise due to technological advancement.</p>
<p>For many workers, though, the promise of cheaper goods and services means little if they <a href="https://www.benzinga.com/startups/24/02/37203455/google-lays-off-thousands-more-employees-despite-record-profits-one-year-after-laying-off-12-000-emp">no longer have a steady income</a>. The AI revolution may drive economic efficiency, but whether it results in a society that benefits everyone remains to be seen.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2"><strong>You can invest today for just $0.26/share with a $1000 minimum.</strong></a></strong></li>
<li><strong>If there was a new fund backed by Jeff Bezos offering a</strong><strong> <a href="https://www.benzinga.com/money/arrived-private-credit-fund"><strong>7-9% target yield with monthly dividends would you invest in it</strong></a>?</strong></li>
</ul>


Wages Will Crash, But So Will Prices, Says Leading AI Investor Marc Andreessen On AI's Role In Ushering A Productivity-Fueled Consumer Boom

<p>Waste Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) has outperformed the market over the past 10 years by 4.29% on an annualized basis producing an average annual return of 15.54%. Currently, Waste Management has a market capitalization of $89.66 billion. </p>
<p><strong>Buying $1000 In WM:</strong> If an investor had bought $1000 of WM stock 10 years ago, it would be worth <strong>$4,252.43</strong> today based on a price of $223.38 for WM at the time of writing.</p>
<h3>Waste Management's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1738770309_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

WIIM

UnitedHealth Group shares are trading lower following a now-deleted post on X from Bill Ackman stating he would short the stock.

<p><strong>Aurora Cannabis Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) stock surged more than 45% on Wednesday morning following the release of its <a href="https://www.benzinga.com/news/earnings/25/02/43496003/aurora-cannabis-stock-jumps-on-record-breaking-q3-earnings">third-quarter fiscal 2025 earnings</a>, which revealed a substantial increase in revenue and profitability. The company reported total net revenue of CA$88.2 million ($61.74 million), up 37% year-over-year, driven largely by a 51% jump in its global medical cannabis business.</p>
<p>&#8220;This quarter was record-breaking for Aurora, driven by all-time highs in global medical net revenue, net income, adjusted EBITDA, and free cash flow,&#8221; said <strong>Miguel Martin,</strong> Aurora's executive chairman and CEO. The company also posted a net income of CA$31.2 million, a 282% year-over-year increase, and an adjusted EBITDA of CA$23.1 million, up 316%.</p>
<h2 class="wp-block-heading">Cannabis Stocks Rally In Sympathy?</h2>
<p>The strong earnings report triggered a broader rally in the cannabis sector, with several companies experiencing notable gains:</p>
<ul>
<li><strong>Canopy Growth Corp. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) jumped over 23%.</li>
<li><strong>Tilray Brands Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) climbed more than 10%.</li>
<li><strong>Cronos Group Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRON#NASDAQ">CRON</a>) rose approximately 8%.</li>
</ul>
<p>Investors appear to be reacting positively to Aurora's performance, particularly its growing international medical cannabis revenues and improved profitability.</p>
<h2 class="wp-block-heading">Do Trade Tensions Play A Role?</h2>
<p>Beyond earnings, another factor likely contributing to the sector-wide rally is the 30-day delay in U.S.-Canada tariffs, a move that has eased investor concerns. The Trump administration postponed the imposition of 25% tariffs on Canadian imports, providing a window for further trade negotiations. While cannabis wasn't explicitly mentioned in the tariff discussions, the broader economic impact on trade between the countries may be influencing sentiment toward Canadian cannabis companies.</p>
<p>As Aurora continues to expand its medical cannabis footprint globally, investors are closely watching whether the company can sustain its momentum in upcoming quarters.</p>
<p><em>Illustration made with Canva.</em></p>


Cannabis

Equities

Movers

CRON

TLRY

Why Aurora Cannabis Stock Is Skyrocketing Wednesday: What About Canopy, Tilray, Cronos?

HCAI

Huachen AI Parking Management Technology Holding Shares Resumed Trade

SNAP

Snap shares are trading lower following Q4 financial results. The stock initially rose on the report but reversed on Wednesday. Wells Fargo downgraded the stock from Overweight to Equal-Weight.

<p>B of A Securities  analyst Tim Anderson   maintains Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) with a Buy and lowers the price target from $118 to $112.</p>


B of A Securities Maintains Buy on Merck & Co, Lowers Price Target to $112

<p><a href="https://clinicaltrials.gov/study/NCT05026177" title="https://clinicaltrials.gov/study/NCT05026177">https://clinicaltrials.gov/study/NCT05026177</a></p>


SAVA

Cassava Sciences Terminates Simufilam REFOCUS-ALZ Alzheimer's Disease Clinical 
Trial.

IDEX shares are trading lower following mixed Q4 financial results.

Huachen AI Parking Management Technology Holding Shares Resumed Trade Then Again Halted On Circuit Breaker To The Downside

Nomura Holdings shares are trading higher following Q3 financial results.

Agnico Eagle Mines Option Alert: Jan, 2026 $125 Calls at the Ask: 2000 @ $5.8 vs 639 OI; Earnings 2/13 After Close Ref=$99.08

<p>B of A Securities  analyst Steve Byrne   downgrades FMC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>) from Neutral to Underperform and lowers the price target from $61 to $48.</p>


Downgrades

B of A Securities Downgrades FMC to Underperform, Lowers Price Target to $48

<p>Wells Fargo  analyst Chris Carey   maintains Mondelez International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>) with a Equal-Weight and lowers the price target from $61 to $54.</p>


MDLZ

Wells Fargo Maintains Equal-Weight on Mondelez International, Lowers Price Target to $54

TROW

T. Rowe Price shares are trading lower after the company missed Q4 earnings and revenue estimates.

Press Releases

OTC Markets Group Welcomes Medicenna Therapeutics Corp. to OTCQX

Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Medicenna Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA® (pembrolizumab) at the 39th Annual Meeting of SITC

Medicenna Announces Upcoming Presentations at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS)

Earnings

Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update

Medicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO)

Updated MDNA11 Monotherapy and Combination Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to be Presented at the 2024 Immunotherapy Bridge Conference

Medicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA® (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study

Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)

Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025

OTCM

Medicenna Therapeutics

Comments

Medicenna Therapeutics

Medicenna Therapeutics (MDNAF) Forecast

Medicenna Therapeutics (OTC:MDNAF) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga